{"doi":"10.1016/j.jaad.2020.01.019","title":"Health care regulation, the Food and Drug Administration (FDA), and access to medicine","abstract":null,"journal":"Journal of the American Academy of Dermatology","year":2020,"id":33902,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":1,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":176498,"name":"Rui Rui Chloe Zheng","orcid":null,"position":1,"is_corresponding":false},{"id":176499,"name":"Zachary A. Doerrer","orcid":null,"position":2,"is_corresponding":false},{"id":176500,"name":"Anastasia O. Kurta","orcid":null,"position":3,"is_corresponding":false},{"id":176501,"name":"Jacob J. Shelley","orcid":null,"position":4,"is_corresponding":false},{"id":176502,"name":"Elaine C. Siegfried","orcid":null,"position":5,"is_corresponding":false},{"id":176497,"name":"Chang Ye Wang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31958530","pmcid":null,"openalex_id":"https://openalex.org/W2999135678","authors":[],"funders":[],"total_grants":0,"fwci":0.6528,"citation_percentile":0.70205814,"influential_citations":0,"citation_trend":[{"year":2021,"count":1},{"year":2022,"count":1}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0190962220300694?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0190962220300694?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jaad.2020.01.019","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31958530","host_type":"repository"}],"fields_of_study":["Pharmaceutical studies and practices","Pharmaceutical Economics and Policy","Pharmaceutical industry and healthcare","Medicine","Law","Political Science"],"mesh_terms":["Child","Dermatitis, Atopic","Health Services Accessibility","Humans","United States","United States Food and Drug Administration","Antibodies, Monoclonal, Humanized"],"keywords":["Medicine","Food and drug administration","Administration (probate law)","Drug","Drug administration","Drug approval","Drug labeling","MEDLINE","Intensive care medicine","Pharmacology","Family medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-09T17:09:48.743855Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}